Dr Barbara Burtness speaks to ecancer about the OrigAMI-4 study.

She says that in patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based chemotherapy and immune checkpoint inhibitors, subcutaneous amivantamab demonstrated strong clinical activity.

The study reported a 47% objective response rate, including complete and partial responses, with rapid tumour shrinkage observed in most patients and a median time to response of just 6.6 weeks.

Responses were durable, with a median duration of 7.2 months, and progression-free survival reached 6.8 months, exceeding historical outcomes in this difficult-to-treat population.

The safety profile was manageable and consistent with EGFR/MET inhibition, with most adverse events being low grade and only a small proportion of patients discontinuing treatment.

Dr Burtness says that these findings highlight amivantamab as a promising targeted therapy option that may significantly improve outcomes in a setting with historically limited and less effective treatments.